Company Snapshot

Investment Thesis

Dexcom designs continuous glucose monitoring (CGM) systems for diabetics and metabolic health consumers. Rapid adoption, international expansion, and new indications deliver high growth.

  • G7 Launch: Smaller, easier-to-use CGM improves adherence.
  • Channel Diversification: Pharmacy and DME distribution broaden access.
  • Digital Ecosystem: Integration with pumps, pens, and apps deepens engagement.

Strategic Mix

Devices CGM transmitters and sensors
Software & Data Clarity analytics and provider dashboards
Geographic U.S., Europe, and emerging markets
Customer Mix Type 1, Type 2, and gestational diabetes patients

Mix reflects Dexcom's CGM-centric business with growing digital services.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Type 2 Opportunity

Reimbursement wins open a large underpenetrated population.

Wearable Integration

Partnerships with Apple, Garmin, and pumps enhance ecosystem.

Manufacturing Scale

New Malaysian and U.S. facilities reduce unit costs.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...